Cellares

Cellares is an Integrated Development and Manufacturing Organization (IDMO) which specializes in cell therapies. From its funding announcement.

$50M Series DRaised 4 months agoSouth San Francisco, USABiotech & PharmaUSA
Visit website →

In their own words

What Cellares says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "Integrated Development and Manufacturing Organization (IDMO) which specializes in cell therapies". Source

Market expansionCommercial growthManufacturing and scale

Public signal Read from the company's own description of what the funding supports.

Why now

Where Cellares is today

Cellares announced a Series D round of $50M on 15 June 2026. AfterRaise has tracked 3 funding events for this company this year, $327M in total.

Latest round
Series D
Amount
$50M
Announced
15 June 2026
Headquarters
South San Francisco, USA
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
Not stated
Also participating
Not stated
Relevant leadership
CEO Fabian Gerlinghaus

Momentum AfterRaise intelligence

AfterRaise Score

72
Building momentum
0 funding signals in the last 90 days
Funding recency
18/40
announced within the last 6 months
Round scale
19/25
round size relative to the market
Funding stage
20/20
Series D
Funding cadence
15/15
3 funding events tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 15 June 2026
    $50M Series D
    Investors not stated in the announcement.
  • 9 June 2026
    $20M raised
    Investors not stated in the announcement.
  • 28 January 2026
    $257M Series D
    Investors not stated in the announcement.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • New market entry
  • First local hires in the new market
  • Local entity and legal setup
  • Commercial team build-out

Opportunities this could create

  • CMC and manufacturing
  • Quality systems
  • Scientific hiring
  • Licensing and BD partnerships
  • Market-entry advisers

Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

Medium momentum6 connected signals across 138 days
  • 15 June 2026$50M Series D announced
  • 9 June 2026Funding round announced
  • 28 January 2026Funding Series D announced
  • 15 June 2026Stated priority: market expansion
  • 15 June 2026Stated priority: commercial growth
  • 15 June 2026Stated priority: manufacturing and scale

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Cellares is open to

Not yet specified

Cellares has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Cellares

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Cellares?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector